Ringaskiddy facility avoids latest review by Novartis of its global sites
In Ireland, Novartis shocked staff and politicians when it said in late 2019 it planned to phase out 320 jobs at Ringaskiddy over three years.
Novartis is going ahead with long-set plans to phase out a total of 320 jobs at Ringaskiddy by the end of next year, but remaining staff at the Co Cork facility have escaped the latest global review announced on Tuesday by the pharma giant of its manufacturing sites.
The Swiss company, like many pharma manufacturers, is constantly reviewing its global manufacturing supply chains and its latest review which it announced as it unveiled its quarterly earnings report has put into question the future of its Sandoz unit that produces off-patent or generic drugs.
